Register for our free email digests:
Latest From F2G Ltd.
FDA should consider allowing sponsors in challenging area of single species antibacterials more flexibility in study designs, advisory committee suggests, despite disagreement over approaches such as animal models and non-inferiority trials.
Payers and prescribers, not just the US FDA, need to understand the basis of approval, John Rex says.
Sponsors lack comprehensive advice on how to access benefits of GAIN legislation's incentives, which include the opportunity for fast track designation, priority review designation and five years of market exclusivity, government watchdog says.
Recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.
- Large Molecule
- Therapeutic Areas
- Immune Disorders
- Metabolic Disorders
- North America
- Parent & Subsidiaries
- Peptimmune Inc.
- Senior Management
- Eric Zanelli, PhD, VP, Research
- Contact Info
Phone: (617) 715-8000
64 Sidney St., Ste. 380
Cambridge, MA 02139
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.